Condition
Rifampicin-resistant Tuberculosis
Total Trials
4
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 3 (1)
Trial Status
Not Yet Recruiting2
Recruiting1
Active Not Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07393438Phase 2Not Yet Recruiting
Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)
NCT07170800Phase 2Recruiting
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
NCT06081361Phase 3Active Not Recruiting
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
NCT06565806Not Yet RecruitingPrimary
French National Cohort of Patients With Rifampicin-Resistant Tuberculosis
Showing all 4 trials